{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.0","upperLimit":"36.4","value":"28.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"161"}],"units":"Participants"}],"description":"The interval from the first documentation of response to the earlier of the first documentation of definitive disease progression or death from any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"All participants in this study received both study drugs and were therefore analysed together as a single treatment arm.\n\nParticipants receiving the different regimens were not analysed separately by regimen, as the study was designed to assess the safety of the combination study treatment.\n\nThe study included N=161 participants who received both acalabrutinib and pembrolizumab and are summarized together (from First stage safety lead-in and Second stage expansion). Stage 3 (additional expansion in subjects with Myelofibrosis) was planned but not conducted.","id":"OG000","title":"Acalabrutinib + Pembrolizumab"}],"paramType":"MEDIAN","populationDescription":"All participants in this study received both study drugs and were therefore analyzed together as a single treatment arm. Participants receiving the different regimens were not analyzed separately by regimen, as the study was designed to assess the the combination study treatment.","reportingStatus":"POSTED","timeFrame":"104 weeks","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"Months"}